- $261.35m
- $134.63m
- $0.85m
Annual balance sheet for Compass Therapeutics., fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 47.1 | 145 | 187 | 152 | 127 |
| Prepaid Expenses | |||||
| Total Current Assets | 50.2 | 147 | 195 | 154 | 133 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.13 | 6.33 | 4.53 | 2.67 | 7.08 |
| Other Long Term Assets | |||||
| Total Assets | 51.9 | 154 | 200 | 157 | 140 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 10.1 | 10.6 | 16.2 | 7.8 | 8.87 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 12 | 13.7 | 18 | 8.34 | 15.2 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 39.9 | 140 | 182 | 149 | 125 |
| Total Liabilities & Shareholders' Equity | 51.9 | 154 | 200 | 157 | 140 |
| Total Common Shares Outstanding |